If the FDA is making abuse-deterrant formulations a priority and the HHS is notably aware of this, Probuphine's classification as being the least likely buprenorphine product to be abused, should factor into the equation....
To classify them all the same isn't doing justice to Probuphine's abuse-deterrant technology.
News 
Market Data 
Discover 
AI
